Transformational Breast Cancer Biomarker Analytics

Dramatically faster breast cancer recurrence  risk profiling

About us

Traditional methods of identifying biomarkers to predict breast cancer recurrence risk are slow and expensive.
Digistain has developed an MHRA-cleared technology that transforms the analysis of key biomarkers from a long costly manual wet-lab process to a rapid affordable AI-enabled solution.
GOLD STANDARD predictive equivalence to traditional genomic risk scoring analytics
CLEAR insights on likelihood of breast cancer recurrence within the next 10 years
FAST actionable results helping reduce treatment decision times
LOWER COST enables many more people to access cancer recurrence prediction tests
SEAMLESS integration with existing clinical workflows

Our Technology

Risk Actionable Information in Under 1 Hour

Digistain was created by a team of world-class cancer specialists to solve the time, cost, availability, and accuracy issues associated with traditional biomarker analytics.
Our optical scan technology captures a unique spectral signature from each biopsy creating over 10,000 data points unique to the individual biology of a patient.  We then use artificial intelligence to analyse the imaging data and calculate a Digistain Prognostic Score that precisely and objectively identifies the risk of cancer recurrence.
time cost 1

Our Science

Our approach is based on over 15 years of research and development pioneered by respected cancer scientists from the NHS, Cancer Research UK and Imperial College together with input from over 1500 oncologists.
The technology has been successfully validated in prominent cancer centres of excellence.  Digistain has demonstrated gold-standard equivalency to NICE-approved traditional tumour profiling NGS tests in disease-free survival and overall survival prediction, with equivalent sensitivity, specificity and reproducibility. 
In an independent study commissioned by Digistain, the technology has also indicated superior health economics with potential savings of £286 million over five years in the UK alone.

Supported by